Natural GLP-1: Ozempic on your plate?

Daniel Platteau

In short: your gut does make GLP-1, the hormone that Ozempic and Wegovy copy. But your GLP-1 is destroyed within one to two minutes, while semaglutide acts for a week: it is not a weaker version of the same thing, it works differently. What is proven: protein, some fibres and the order in which you eat your food slightly increase your GLP-1 peaks after meals and help you feel full. What is not: that a "pro-GLP-1" diet or a supplement gets anywhere near the results of the drug. What to do? Focus on filling meals (protein, pulses, oats, whole foods), be wary of "natural GLP-1" capsules, and talk to your doctor if treatment is on the table.

Updated on 24 October 2026.

On social media, the promise is everywhere: "activate your natural Ozempic". A bit of fibre, a protein shake, a berberine capsule, and your body would do for free what the pharmacy sells for 100 to 400 euros a month. There is a grain of truth in it, and that is what makes the slogan misleading.

For the drugs themselves, their side effects and their risks, see also our article on Mounjaro (in French).

What exactly is GLP-1?

GLP-1 (glucagon-like peptide-1) is a gut hormone. It belongs to the incretin family: hormones that the gut releases when we eat and that prepare the body to receive sugar.

It is made mainly by L cells, scattered through the lining of the small intestine and the colon. When the nutrients of a meal pass by, they release GLP-1 into the blood. Its effects:

• it prompts the pancreas to release insulin, but only when blood sugar is high, which limits the risk of hypoglycaemia;
• it holds back glucagon, the hormone that raises blood sugar;
• it slows stomach emptying: the meal stays in the stomach longer;
• it contributes to satiety, the feeling of having eaten enough.

An often overlooked detail: GLP-1 is also made by a small group of neurons in the brainstem, the part of the brain that connects it to the spinal cord. We will come back to this.

The problem with natural GLP-1: it lasts two minutes

An enzyme found almost everywhere in the body, DPP-4 (dipeptidyl peptidase-4), cuts GLP-1 and inactivates it, largely before it has even left the gut. The kidneys clear the rest. The result: a half-life of one to two minutes. The half-life is the time it takes for half of a substance to disappear.

So your body produces small GLP-1 peaks after each meal, which fall back almost immediately: a brief, local signal, tuned to what you eat.

What Ozempic does: turning a peak into a plateau

Semaglutide, the molecule in Ozempic (diabetes) and Wegovy (obesity), is a modified version of human GLP-1. Novo Nordisk's chemists made two changes:

1. one amino acid was replaced at the exact spot where DPP-4 cuts: the enzyme can no longer get a grip;
2. a fatty acid chain attaches the molecule to albumin, the main protein in blood. Protected in this way, it escapes the kidneys.

The result: a half-life of about one week, hence a weekly injection. Where your GLP-1 lives for two minutes, semaglutide lives about 5,000 times longer.

So the drug does not "boost" your hormone: it sets up a permanent signal, at levels your gut never reaches on its own. In the STEP 1 trial, published in 2021, adults with obesity treated with semaglutide 2.4 mg lost an average of 14.9% of their weight in 68 weeks, compared with 2.4% on placebo, with diet and exercise support in both groups.

Can you boost your GLP-1 through food?

Yes, a little. But as physician Gil Carvalho points out in a video from October 2026, a food that raises GLP-1 for a few minutes does not necessarily make you eat less. What counts is appetite.

Protein: the most solid lever

A meta-analysis of controlled trials published in 2020 in Physiology & Behavior pooled 49 publications on high-protein meals. The result: less hunger, more satiety, a fall in ghrelin (the hunger hormone) and a rise in GLP-1 and CCK, another satiety hormone. The effect on these hormones was only significant from about 35 g of protein per meal, roughly 150 g of chicken or fish, or a generous portion of pulses with a Greek yoghurt.

A paradox worth knowing: in the same analysis, high-protein diets followed for weeks or months no longer improved appetite, and GLP-1 even tended to fall. The body adapts. The authors consider these long-term results inconclusive. The useful effect of protein therefore plays out meal by meal.

The order of foods

A Japanese team compared the same meal eaten in different orders, in 12 people with type 2 diabetes and 10 healthy people (Diabetologia, 2016). Starting with meat or fish, then eating the rice:

• slowed stomach emptying (the meal stayed there two to three times longer);
• lowered the blood sugar peak, significantly in people with diabetes;
• increased GLP-1, especially when meat came first.

It is a small trial, but the habit costs nothing.

Fibre: a real mechanism, uneven results

Some fibres are not digested by you but fermented by bacteria in the colon. They produce short-chain fatty acids (acetate, propionate, butyrate), which stimulate L cells. The mechanism is solid in the lab. In humans, it is more nuanced.

A review published in July 2026 by Dutch researchers (Frontiers in Endocrinology) examined 52 studies with 1,085 participants. The fibres that most often increased GLP-1 were dextrins (4 studies out of 8) and mannans such as guar gum or glucomannan (3 out of 4). Beta-glucan managed it in only 3 studies out of 9, resistant starch in 1 out of 12. The authors stress the small samples (median of 19 participants), the short duration of the studies and their wide heterogeneity.

An older review (Journal of the American College of Nutrition, 2013), covering 38 fibre sources, reached a similar conclusion: most of the fibres tested reduced neither appetite nor the amount eaten at the next meal. Beta-glucan was one of the few exceptions.

Beta-glucan: useful, but not because of GLP-1

The beta-glucan in oats and barley is a viscous fibre: with water, it forms a thick gel that slows stomach emptying, as semaglutide does at the start of treatment. That is probably how it fills you up, more than through GLP-1. EFSA, the European Food Safety Authority, has approved two of its effects: it reduces the rise in blood sugar after a meal (from 4 g per 30 g of carbohydrate) and it contributes to normal LDL cholesterol (from 3 g a day). On the other hand, it rejected the satiety claim for lack of sufficient evidence.

In a well-known Australian study from 1995, which compared 38 foods at equal calories, porridge came third in the satiety ranking, behind fish and boiled potatoes, which came first.

Whole foods rather than blended

A little-known lever: texture. In a trial at Pennsylvania State University (Appetite, 2009), 58 adults were given an apple in slices, apple sauce or juice before lunch, at equal calories. Those who ate the whole apple consumed 15% fewer calories over the whole meal. Adding fibre to the juice made no difference: the form of the food mattered more than its composition.

In practice: rolled oats rather than instant porridge, vegetables in chunks rather than mashed, a piece of meat rather than nuggets, a fruit rather than a smoothie. And above all, don't drink your calories.

Pulses, vinegar and chilli

Pulses (lentils, chickpeas, beans) combine protein and fibre. A 2014 meta-analysis of trials shows that a meal with pulses is more filling. On weight, the effect is small: about 300 g of extra weight lost over six weeks on average, in a 2016 meta-analysis.

Vinegar and chilli are often mentioned. An Iranian trial from 2018 (39 people on a diet, 12 weeks) found greater weight loss with two tablespoons of apple cider vinegar a day, but it is too small to draw conclusions. For chilli, the measured effects are small.

Is natural GLP-1 enough to lose weight?

Nothing shows that it is. No study has compared a "pro-GLP-1" diet with semaglutide, and the rises measured after a meal are in no way comparable to exposure to the drug.

There is, however, one argument in favour of home-made GLP-1. The appetite-suppressing effect of the drugs is thought to work largely through GLP-1 receptors in the brain. But gut GLP-1 does not need to reach the brain through the blood: it also acts on the endings of the vagus nerve, which connects the gut to the brainstem. A modest rise in blood levels could therefore have more effect on appetite than the numbers suggest. It is plausible. It is not proven.

Above all, appetite depends on many hormones besides GLP-1 (ghrelin, CCK, PYY, leptin). The most effective levers act on several at once: protein, fibre, whole foods. That is useful for everyone, including people on treatment. But it is not a "natural Ozempic".

In this video (October 2026), Gil Carvalho reviews the foods presented as "natural Ozempic". We checked the main studies he cites (whole apple versus apple sauce, satiety ranking, vinegar, protein): they do say what he says they say, and he points out their limits himself.

Beware of "GLP-1 booster" capsules

The market has spotted the opportunity: berberine, "GLP-1 support" blends, probiotics or plant extracts endorsed by celebrities. The word GLP-1 on the label proves nothing.

• No supplement has shown an effect on weight comparable to a GLP-1 agonist in a serious trial.
• Berberine has some effect on blood sugar in small trials, but it can interact with medicines, and its safety during pregnancy and breastfeeding has not been established.
• The real content of capsules sold online is not checked.

Worse: fake Ozempic is in circulation. In August 2025, the FAMHP, Belgium's federal medicines agency, reminded the public that these GLP-1 analogues are dispensed only on prescription, in a pharmacy, and that a product sold online without a prescription is always a falsified product, with very high risks. On 20 October 2026, it again warned against their misuse and off-label use for weight loss. In 2025, the Belgian Poison Centre also reported a rise in calls about overdoses of these drugs: taking more does not make you lose weight faster.

Who is the drug for, who is the plate for?

BMI: weight in kilos divided by the square of height in metres.

One point matters for anyone considering the drug: the weight often comes back when you stop. In the year after the end of the STEP 1 trial, participants regained about two thirds of the weight they had lost. This was one of the reasons given by the federal health minister, Frank Vandenbroucke, for refusing reimbursement of Wegovy in June 2026, following the advice of the INAMI/RIZIV: it is a long-term treatment with a potentially huge cost. In Belgium, anti-obesity drugs therefore remain at the patient's expense.

In practice: a "pro-satiety" day

No miracle recipe, but a way of combining the documented levers:

• Breakfast: rolled oats (not instant) with plain Greek yoghurt, berries and a few nuts. Protein, beta-glucan and whole foods.
• Lunch: a lentil or chickpea salad with chunky vegetables and a vinaigrette. Start with the salad, finish with the bread.
• Snack: a whole apple, a raw carrot, a handful of almonds. No juice.
• Dinner: fish or meat with vegetables, eaten before the potatoes (boiled, not mashed).

Most Belgians are far from this: according to Sciensano's food consumption survey (2022-2023), we eat an average of 16 g of fibre a day, while EFSA recommends 25 g for an adult. Increasing fibre gradually avoids bloating.

When to see a doctor? If your weight bothers you in everyday life, if you have diabetes, high blood pressure or sleep apnoea, or if you are considering a weight-loss drug: your GP is the right person to talk to, and an accredited dietitian can support you.

And what about the drugs in 2026?

• the Wegovy pill (oral semaglutide 25 mg a day) was authorised in the European Union on 15 July 2026. Weight loss in the OASIS 4 trial: about 17% in 64 weeks;
• orforglipron (Foundayo, Eli Lilly), a pill that can be taken without meal restrictions, is authorised in the United States (April 2026) and the United Kingdom (August). The scientific committee of the European Medicines Agency (EMA) gave a positive opinion in mid-October 2026. It is less powerful than the injections: about 12% weight loss in 72 weeks.

These drugs remain prescription-only, with side effects that are mainly digestive (nausea, vomiting, diarrhoea, constipation) and contraindications. They are a matter for a doctor, not a forum.

Going further: why natural GLP-1 "leaks"

DPP-4 cuts off the first two amino acids of GLP-1 (a histidine and an alanine). The active form, called GLP-1 (7-36), then becomes GLP-1 (9-36), an inactive form. The enzyme sits on the blood vessels of the gut itself, so a large part of GLP-1 is inactivated before it even reaches the general circulation. This is also the principle behind another family of diabetes drugs, the gliptins (sitagliptin, for example): by blocking DPP-4, they double or triple natural GLP-1. Their effect on weight is nil or almost nil, which clearly shows that natural GLP-1, even when increased, remains far from an agonist such as semaglutide.

Semaglutide carries an artificial amino acid (Aib) at position 8 that DPP-4 cannot cut. Orforglipron is no longer a peptide but a small chemical molecule that withstands digestion: it is swallowed like an ordinary pill.

This article is for information only and does not replace the advice of a doctor or pharmacist.

Sources

Belga. (2026, 3 June). Pas de remboursement pour le Wegovy (Vandenbroucke). Le Spécialiste. https://www.lespecialiste.be/fr/actualites/geen-terugbetaling-van-wegovy-vandenbroucke.html

Brussels Times. (2025, 4 November). Overdoses from drugs used for weight loss on the rise in Belgium. https://brusselstimes.com/belgium/1823917/overdoses-from-weight-loss-drugs-on-the-rise-in-belgium/

Carvalho, G. [Nutrition Made Simple!]. (2026, 22 October). Foods That Trigger GLP-1? Here's What Studies Actually Show [Video]. YouTube. https://youtu.be/u5pjKa03lq4

Clark, M. J., & Slavin, J. L. (2013). The effect of fiber on satiety and food intake: a systematic review. Journal of the American College of Nutrition, 32(3), 200-211. https://doi.org/10.1080/07315724.2013.791194

de Jong, J. C. B. C., Lentjes, M. G. W., Pietersma, K. F., Pasman, W. J., Wopereis, S., & Hoevenaars, F. P. M. (2026). Dietary fibers to boost endogenous GLP-1 secretion and satiety: a scoping review. Frontiers in Endocrinology, 17, 1880500. https://doi.org/10.3389/fendo.2026.1880500

EFSA NDA Panel. (2011). Scientific Opinion on the substantiation of health claims related to beta-glucans from oats and barley and maintenance of normal blood LDL-cholesterol concentrations, increase in satiety leading to a reduction in energy intake, reduction of post-prandial glycaemic responses and digestive function. EFSA Journal, 9(6), 2207. https://doi.org/10.2903/j.efsa.2011.2207

FAMHP. (2025, 25 August). Faux médicaments amaigrissants : méfiez-vous des arnaques sur les réseaux sociaux. Federal Agency for Medicines and Health Products. https://news.belgium.be/fr/node/41031/pdf

FAMHP. (2026, 20 October). Les analogues du GLP-1 et les doubles analogues GIP/GLP-1 : risques associés au mésusage. Federal Agency for Medicines and Health Products. https://www.afmps.be/fr/news/les_analogues_du_glp_1_et_les_doubles_analogues_gipglp_1_risques_associes_au_mesusage_et_a

Flood-Obbagy, J. E., & Rolls, B. J. (2009). The effect of fruit in different forms on energy intake and satiety at a meal. Appetite, 52(2), 416-422. https://doi.org/10.1016/j.appet.2008.12.001

Healio. (2026, 1 April). FDA approves Foundayo, an oral GLP-1, for adults with obesity. https://www.healio.com/news/endocrinology/20260401/fda-approves-orforglipron-an-oral-glp1-for-adults-with-obesity

Holst, J. J. (2007). The physiology of glucagon-like peptide 1. Physiological Reviews, 87(4), 1409-1439. https://doi.org/10.1152/physrev.00034.2006

Holt, S. H., Miller, J. C., Petocz, P., & Farmakalidis, E. (1995). A satiety index of common foods. European Journal of Clinical Nutrition, 49(9), 675-690.

Khezri, S. S., Saidpour, A., Hosseinzadeh, N., & Amiri, Z. (2018). Beneficial effects of apple cider vinegar on weight management, visceral adiposity index and lipid profile in overweight or obese subjects receiving restricted calorie diet: a randomized clinical trial. Journal of Functional Foods, 43, 95-102. https://doi.org/10.1016/j.jff.2018.02.003

Kim, S. J., de Souza, R. J., Choo, V. L., et al. (2016). Effects of dietary pulse consumption on body weight: a systematic review and meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition, 103(5), 1213-1223. https://doi.org/10.3945/ajcn.115.124677

Kohanmoo, A., Faghih, S., & Akhlaghi, M. (2020). Effect of short- and long-term protein consumption on appetite and appetite-regulating gastrointestinal hormones, a systematic review and meta-analysis of randomized controlled trials. Physiology & Behavior, 226, 113123. https://doi.org/10.1016/j.physbeh.2020.113123

Kuwata, H., Iwasaki, M., Shimizu, S., et al. (2016). Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial. Diabetologia, 59(3), 453-461. https://doi.org/10.1007/s00125-015-3841-z

Lasker Foundation. (2024). GLP-1-based therapy for obesity. https://laskerfoundation.org/winners/glp-1-based-therapy-for-obesity/

Li, S. S., Kendall, C. W. C., de Souza, R. J., et al. (2014). Dietary pulses, satiety and food intake: a systematic review and meta-analysis of acute feeding trials. Obesity, 22(8), 1773-1780. https://doi.org/10.1002/oby.20782

Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130. https://doi.org/10.1016/j.molmet.2019.09.010

Novo Nordisk. (2026, 15 July). Novo Nordisk receives European Commission approval of Wegovy pill as first oral GLP-1 for weight management in the EU. BioSpace. https://www.biospace.com/press-releases/novo-nordisk-receives-european-commission-approval-of-wegovy-pill-as-first-oral-glp-1-for-weight-management-in-the-eu-single-ready-to-use-pen-for-higher-dose-7-2-mg-also-approved

PharmaNow. (2026, 16 October). EMA CHMP October 2026 meeting highlights: orforglipron, biosimilars. https://www.pharmanow.live/latest-news/ema-chmp-october-2026-meeting-highlights-orforglipron-biosimilars

Sciensano. (2025). Results of the national food consumption survey 2022-2023: carbohydrates, mono- and disaccharides, dietary fibre, sugary drinks. Sciensano. https://www.sciensano.be/en/results-national-food-consumption-survey-2022-2023

Test-Achats. (2025, 9 October). Prescription d'Ozempic, Wegovy et Mounjaro en Belgique. https://www.test-achats.be/sante/maladies-et-medicaments/medicaments/news/prescription-ozempic-wegovy-mounjaro-belgique

UK Medicines and Healthcare products Regulatory Agency. (2026, 10 August). UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. GOV.UK. https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes

Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183

Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. https://doi.org/10.1111/dom.14725